Simon Brack
Head of Strategic Analysis, External Scientific Innovation Johnson & Johnson
Simon Brack is Senior Director and Head of Strategic Analysis, External Scientific Innovation at Johnson & Johnson Innovative Medicine, where he leads a global team responsible for evaluating breakthrough therapeutic modality innovations and strategic partnership opportunities. Combining deep scientific expertise with strategic business insight, he helps guide investment and collaboration decisions across therapeutic areas from a modality perspective. Previously, Simon led strategic analysis and competitive intelligence efforts focused on cell and gene therapies within Discovery, Product Development & Supply (DPDS) External Innovation. Before joining Johnson & Johnson, he was part of Covagen, an ETH Zurich spin-off acquired by Johnson & Johnson in 2014, where he led multispecific antibody programs in immuno-oncology. Simon holds a PhD from ETH Zurich.
Seminars
- Reviewing how emerging clinical data is shaping market perspectives on in vivo cell therapies to guide smart pipeline decisions
- Examining the resurgence of next-generation in vivo CAR-Ts and ex vivo explorations for solid tumours and autoimmune disease to identify where each modality can unlock the greatest opportunity
- Aligning scientific, manufacturing, regulatory and commercial perspectives on the future direction of the field to accelerate clinical impact
